Abstract Purpose: Small cell lung cancer (SCLC) possesses high tendency to disseminate. However, SCLC patients with paraneoplastic syndrome mediated by immunity against onconeural antigens remain in limited-stage disease (LD) without distant metastases. Cumulative evidence regulates that a balance between immune and regulatory T (Treg) cells determines the magnitude of immune responses to not only self-antigens but also tumor-associated antigens. The purpose of this study was to elucidate the immunologic balance induced in SCLC patients. + T-cell balance may be a biomarker that distinguishes ED-SCLC from LD-SCLC and predicts recurrence. This study also suggests the importance of inducingTeff cells, particularlyTh17 cells, while eliminatingTreg cells to control systemic dissemination of SCLC.
) produced IFN-g, interleukin (IL)-4, and IL-17, thus considered to be immune effector T cells (Teff). Significantly more Teff cell numbers were detected in LD-SCLC patients than that of extended-stage SCLC (ED-SCLC). By contrast, induction of CD62L high CD25
+ CD4 + Treg cells was significantly higher in ED-SCLC patients. Long-term survivors of SCLC maintained a highTeff toTreg cell ratio, whereas patients with recurrent disease exhibited a lowTeff toTreg cell ratio. Teff cells in LD-SCLC patients included more IL-17^producing CD4 + T cells (Th17). Moreover, dendritic cells derived from CD14
+ cells of LD-SCLC patients secreted more IL-23.
Conclusion: These results show that CD4
+ T-cell balance may be a biomarker that distinguishes ED-SCLC from LD-SCLC and predicts recurrence. This study also suggests the importance of inducingTeff cells, particularlyTh17 cells, while eliminatingTreg cells to control systemic dissemination of SCLC.
Small cell lung cancer (SCLC) is an aggressive disease with a strong tendency to disseminate. Approximately 15% to 20% of SCLC patients whose tumors are confined to the hemithorax and mediastinum and lack detectable distant metastases are considered to be limited-stage disease (LD). These LD-SCLC patients are often cured by treatment management. However, although no distant metastases are detected in LD-SCLC patients, regional treatments such as surgical resection or thoracic radiation therapy alone seldom result in a cure suggesting systemic micrometastases. Thus, repeated invasion by SCLC cells into the peripheral blood, some of which remain in the blood as circulating tumor cells, is considered to occur not only in extended-stage disease (ED) patients possessing prominent distant metastases but also in LD patients (1, 2) . The reason why circulating tumor cells are unable to establish visible distant metastases in LD patients is unclear because no biological differences have been detected between tumor cells of LD-SCLC and ED-SCLC.
SCLC is considered to be a relatively immunogenic tumor because it occasionally causes paraneoplastic syndromes such as the Lambert-Eaton myasthenic syndrome (LEMS) mediated by an immunologic mechanism that recognizes shared onconeural antigens. Interestingly, SCLC patients suffering from LEMS tend to remain in long-term LD state and have favorable prognoses (3) . Thus, it is postulated that the immune response, which attacks the neuromuscular system in LEMS patients, also fights the SCLC cells to constrain tumor progression.
In the immune system, regulatory CD4 + T (Treg) cells with constitutive expression of the interleukin (IL)-2 receptor a chain (CD25) and the transcription factor forkhead box P3 (FOXP3) play a pivotal role in peripheral tolerance to self and non-self antigens, including tumor-associated antigens (4) . It has been shown that Treg cell numbers increase in cancerbearing patients and that the number of Treg cells correlates with the prognosis (5 -10). We have reported that in addition to tumor-specific Treg cells, antitumor effector T (Teff) cells were generated in the same tumor-draining lymph nodes during tumor progression (11) . T cells with down-regulated CD62L expression (CD62L low ) that were isolated from the tumor-draining lymph nodes mediated antitumor reactivity when infused i.v., resulting in the regression of established tumors (12, 13 
Materials and Methods
Patients. The present study comprised 35 consecutive SCLC patients, 8 long-term survivors, and 19 healthy volunteers from a single institution (Niigata University Medical and Dental Hospital, Niigata, Japan; Table 1 ). LD-SCLC patients who had been disease-free for >3 y after treatment were considered to be long-term survivors. Specimens were collected after obtaining written informed consent approved by the Niigata University Ethical Committee.
Cell purification. PBMCs were obtained by centrifugation over Ficoll-Hypaque gradients. CD4 + and CD8 + T cells were purified by positive selection using CD4 + or CD8 + T-cell isolation kits (Dynal nonessential amino acids, 1 Amol/L sodium pyruvate, 100 units/mL penicillin, and 100 Ag/mL streptomycin sulfate (all from Life Technologies, Inc.).
Antibodies and phenotype analyses. The following mAbs were used: FITC-conjugated anti-CD3 (HIT3a) and CD4 (RPA-T4), phycoerythrin (PE)-conjugated anti-CD8 (RPA-T8) and CD25 (M-A251), PE-Cy7 -conjugated anti-CD25 (M-A251), PE-Cy5 -conjugated anti-CD62L (Dreg 56; all from BD PharMingen), and FITC-conjugated anti-CD62L (Dreg 56; eBioscience). Cell surface phenotypes were analyzed by direct immunofluorescence staining of 1 Â 10 6 cells with conjugated mAbs. In each sample, 10,000 cells were analyzed using a FACScan flow microfluorometer (Becton Dickinson) and CellQuest software. Staining of cytosolic FOXP3 was done using PE-anti-human FOXP3 mAb (PCH101) and Staining set (eBioscience), according to the manufacturer's instructions. Statistical analyses. P values were calculated by using two-sided Student's t test; P < 0.05 was considered to be statistically significant. For comparison of percentages of cells from the same patients before and after chemotherapy, a paired t test was used instead.
Results

Shifted CD4
+ regulatory and effector balance in patients with LD-SCLC and ED-SCLC. Before purification, PBMCs were analyzed for CD3, CD4, CD8, CD62L, and CD25 expression. (Fig. 1C) . The healthy volunteers included individuals both younger than (<40 years) and as old as the SCLC patients. No differences were observed between them with regard to the percentages of CD62L low and CD62L high CD25 + cells. Consistent with previous studies that showed that the Treg cell subpopulation increases in cancerbearing patients (14 -20) , the CD62L high CD25 + subpopulation significantly increased in ED-SCLC patients compared with the healthy volunteers (P = 0.0009). In contrast, the percentages of the CD62L high CD25 + subpopulation in LD-SCLC patients showed no differences from those of the healthy volunteers. Further, a significantly larger CD62L low T-cell subpopulation was induced in the LD-SCLC patients compared with that in the healthy volunteers or ED-SCLC patients (P = 0.000009 and 0.00003, respectively; Fig. 1C Fig. 1D , a distinct CD62L low T-celldominant CD4 + T-cell balance was induced in LD-SCLC patients, whereas a CD62L high CD25 + CD4 + T-cell -dominant balance was observed in ED-SCLC patients. This study included four LEMS patients. All of them were LD-SCLC patients and exhibited effector-dominant CD4 + T-cell balance. In contrast to the percentages of CD4 + cells, the percentages of CD62L low primed effector CD8 + T cells show no differences among LD-SCLC and ED-SCLC patients and healthy volunteers ( Fig. 1E  and F + T-cell subpopulation. Next, we examined the cytokine production profile of each T-cell subpopulation. Sufficient number of purified T cells for cytokine analyses were obtained from 6 healthy volunteers, 10 LD-SCLC patients, and 7 ED-SCLC patients. Purified T cells were stimulated with immobilized anti-CD3 mAbs, and the supernatant was analyzed for IFN-g, tumor necrosis factor-a, IL-2, IL-4, IL-5, and IL-17 by BD-CBA or ELISA according to the manufacturer's instructions. Figure 3A shows a representative cytokine production profile obtained from one of the LD-SCLC patients. CD62L low CD4 + T cells secreted large amounts of Th1, Th2, and Th17 cytokines, such as IFN-g, tumor necrosis factor-a, IL-4, IL-5, and IL- 17 (21 -28) . Moreover, recently, it was shown that Th17 cells mediated potent antitumor reactivity to eradicate large established tumor (29) . Th1 cells also have been considered to play an important role in antitumor immunity. To determine the size of the CD4 + T-cell subpopulation secreting IL-17, or IFN-g, CD4 + T cells isolated from SCLC patients and healthy volunteers were stimulated with immobilized anti-CD3 mAb, and the supernatants were quantified for IL-17A and IFN-g using ELISA. As shown in Fig. 3B, CD62L low CD4 + T cells isolated from LD-SCLC patients produced significantly more IL-17A than those isolated from ED-SCLC and healthy volunteers (P = 0.012 and 0.004, respectively). In contrast, levels of IFN-g produced by the same number of CD62L low CD4 + T cells showed no difference among the LD-SCLC and ED-SCLC patients and healthy volunteers (Fig. 3C) . Thus, it is likely that Teff cells induced in LD-SCLC patients deviated to Th17 cells. IL-23 produced by DCs is believed to play a critical role in expanding a Th17 subpopulation (30) . It was reported that DCs derived from monocytes of the multiple sclerosis patients, in whom Th17 cells are highly pathogenic and essential, produced more IL-23 (24) . Then, we tested if DCs derived from CD14 + cells of the SCLC patients secrete IL-23. As shown in Fig. 3D , DCs derived from the LD-SCLC patients produced significantly more IL-23 on lipopolysaccharide stimulation.
Autologous tumor antigen -specific IFN-g production by CD62L
low T cells derived from LD-SCLC patients. Next, to assess whether the CD62L low subpopulation comprised T cells that recognize antigens on autologous SCLC tumor cells, we evaluated cytokine production by T cells isolated from a stage IB LD-SCLC patient who had undergone surgical resection and adjuvant chemotherapy. The resected tumor was digested with a mixture of 0.1% collagenase, 0.01% DNase, and 2.5 units/mL hyaluronidase (Sigma) for 3 hours at room temperature. Tumor cells were cryopreserved by supplementation with 5% DMSO and 6% hydroxyethyl starch cryoprotectant mixture (CP-1; Kyokuto) at -80jC according to the manufacturer's instructions until they were used for coculture. CD62L low CD4 + T cells, CD62L high CD25 low CD4 + T cells, or CD62L low CD8 + T cells isolated from the peripheral blood of the patient were stimulated with monocyte-derived DCs pulsed with 50 Gyirradiated autologous tumor cells. One million monocytederived DCs were cocultured with 1 Â 10 6 tumor cells in 2 mL of CM for 24 hours. CD11c + cells were further purified with CD11c microbeads and autoMACS after coculture for T-cell stimulation. In a 96-well plate, 1 Â + Tcells. LS, long-term survivors who had been disease-free for >3 y after treatment; RD, LD-SCLC patients who had recurrent disease after treatment. #, patients who had local recurrent diseases without distant, hematogenous metastases. *, P < 0.01; **, P < 0.05, compared with healthy volunteers.
In contrast, the naive CD62L high CD25
-CD4 + T-cell subpopulation did not show tumor antigen -specific IFN-g release. Moreover, the addition of CD62L high CD25 + CD4 + T cells inhibited tumor-specific IFN-g secretion. CD62L
low CD8 + T cells also showed antigen-specific IFN-grelease.
Effect of chemotherapy on Teff to Treg cell ratio. It has been perceived that chemotherapy affects the general immune responsiveness in treated patients. However, recent studies indicated that certain cytotoxic agents may augment immune reactivities by reducing the number of Treg cells (31 -33) . To address the effects of chemotherapy on CD4 + T-cell balance, T cells obtained from PBMCs were examined after two courses of platinum-based chemotherapy and analyzed using the paired Student's t test. Seven LD-SCLC and five ED-SCLC patients were included for the analyses. Eight patients were treated with cisplatin (CDDP) and etoposide; three patients, with carboplatin (CBDCA) and etoposide; and one patient, with CBDCA, ifosfamide, and etoposide. The peripheral blood was obtained from patients whose WBC count recovered to >3,000/AL 18 to 20 days after the last chemotherapy session. As shown in Fig. 4A , the percentages of CD62L low cells from the total number of CD4 + T cells increased significantly (P = 0.003). In contrast, the percentage of Treg cells decreased (P = 0.003; Fig. 4B ). Thus, platinum-based chemotherapy increased the Teff to Treg cell ratio (P = 0.004; Fig. 4C ). It is probable that Treg cells is more sensitive to chemotherapeutic agents and that Teff cells possess a potent ability to proliferate. Thus, even in the ED-SCLC patients, the level of Treg cells significantly decreased and Teff cells readily proliferated after chemotherapy, resulting in an increase in the Teff to Treg cell ratio. During certain periods after chemotherapy, the LD-SCLC and the ED-SCLC patients exhibited high Teff to Treg cell ratio without significant differences.
Effector CD4 + T cells dominant in long-term survivors. We analyzed whether the effector-dominant CD4 + T-cell balance was maintained in SCLC patients who had been cured by treatment. As shown in Fig. 5 , long-term survivors still retained significantly greater levels of CD62L low CD4 + Teff cells compared with healthy volunteers (P < 0.00001). Although long-term survivors exhibited significantly but slightly greater levels of Treg cells than those in healthy volunteers (P < 0.01), their effector-dominant CD4 + T-cell balance was the same as that in LD-SCLC patients before treatment (Figs. 1D and E and 5). In contrast, the percentages of CD4 + Teff cells in LD-SCLC patients with recurrent disease were as low as those in ED-SCLC patients, although they had been diagnosed with LD-SCLC before treatment. In Fig. 5 , the number indicates that recurrent disease was confined to the LD state. These patients without distant, hematogenous disease still maintained relatively effector-dominant balance.
Discussion
In this study, we showed the presence of a distinct reciprocal balance between Treg and Teff cells in the peripheral blood of LD-SCLC and ED-SCLC patients. LD-SCLC patients exhibited a unique effector-dominant CD4 + T-cell balance. Moreover, Teff cells induced in LD-SCLC patients included a larger Th17 cell subpopulation. In contrast, ED-SCLC patients exhibited Treg cell -dominant balance. The manner in which the distinct CD4 + T-cell balance is generated in cancer-bearing hosts remains unclear. In several human malignancies, it was reported that Treg cells were induced in tumor microenvironments and tumor-draining lymph nodes (10, 14, 16, 17, 34, 35 Th17 cells develop via a lineage distinct from the Th1 and Th2 lineages and play an essential role in a variety of autoimmune diseases, such as multiple sclerosis (21 -26, 28) . It was shown that monocyte-derived DCs from multiple sclerosis patients produced more IL-23 and that expansion of the pathogenic Th17 subpopulation was driven by IL-23 (30, 39) . We detected that monocyte-derived DCs from LD-SCLC produced more IL-23 than that from ED-SCLC patients. Thus, it is likely that DCs in LD-SCLC patients have tend to expand a Th17 subpopulation. Recently, it was shown that Th17 and Treg cells are reciprocally induced depending on the cytokine balance (40) . Transforming growth factor-h alone induces Treg cells; however, the addition of IL-6 to transforming growth factor-h results in Th17 cell differentiation and inhibits Treg cell induction. It is known that Th17 cells secrete not only IL-17 but also IL-6. Thus, it is possible that deviation to Th17 inhibits Treg cell development and facilitates priming of Th17 as a positive feedback mechanism in LD-SCLC patients.
It remains uncertain if the effector-dominant CD4 + T-cell balance did in fact prevent distant metastases in LD-SCLC patients. In murine models, the adoptive transfer of tumor antigen -reactive effector CD62L low CD4 + T cells tilted the Treg cell -dominant CD4 + T-cell balance toward a dominant Teff cell environment that resulted in the regression of the growing tumor (13) . Moreover, adoptive transfer of Treg cells isolated from tumor-draining lymph nodes promoted tumor growth (11) . Recently, it was reported that Th17-polarized cells mediated eradication of large established tumor and that IL-23 worked as a cancer vaccine adjuvant to increase antitumor T cells and enhance effector T-cell function (29, 41) . Thus, it is likely that the effector-dominant CD4 + T-cell balance and Th17-polarized cells induced in LD-SCLC patients is not only a result but also plays a role in the defense mechanism against tumor cells. Consistent with this theory, the long-term survivors maintained their effector-dominant CD4 + T-cell balance, whereas LD-SCLC patients with recurrent disease due to distant metastases acquired Treg cell -dominant balance.
In contrast to CD4 + T cells, the size of the effector CD8 + T-cell population, which exhibited tumor antigen specificity, was not affected by disease stages or by distinct CD4 + T-cell balance in SCLC patients. Although it has been reported that Treg cells can suppress either CD4 + or CD8 + effector T-cell proliferation (42 -44) , recent in vivo studies showed that antigen-specific CD8 + T cells undergo essentially normal clonal expansion and effector differentiation in the presence of antigen-specific Treg cells (45 -48) . Our proliferation assays indicated that the Treg cells derived from SCLC patients delayed effector CD8 + T-cell proliferation but did not inhibit it (data not shown). Thus, Treg cells may suppress a terminal effector function but not the size of the effector CD8 + T-cell population (48) .
The ratio of effector CD4 + cells in relation to Treg cells could be a useful biomarker for assessing immunologic responses and distinguishing LD-SCLC patients from ED-SCLC patients. Further, the data in this article shed light on the significance of IL-23/Th17 axis for antitumor immunity. Furthermore, these results indicated that immunotherapy that increases tumorreactive Teff cell levels and depletes Treg cells, thereby maintaining a Th17 cell-dominant CD4 + T-cell balance, may be essential in establishing effective antitumor immunity.
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